Likewise, recent studies have indicated that the insulin/IGF axis may have a role in metabolic disorders, namely during the de-activation of aberrant IFN stimulation, contributing to the development of a successful strategy to prevent harmful IFN signaling [80]. This evidence concerns the gene IFNA1 and metabolic disease.